Clinical feasibility study of protrach dualcare a new speaking valve with heat and moisture exchanger for tracheotomized patients

Objective The aim of this study was to evaluate the clinical feasibility of the ProTrach DualCare (Atos Medical, Hörby, Sweden), a device combining a hands‐free speaking valve and a Heat and Moisture Exchanger (HME) for tracheotomized patients. Study Design A non‐randomized, prospective single cente...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Laryngoscope Investigative Otolaryngology 2017-12, Vol.2 (6), p.453-458
Hauptverfasser: de Kleijn, B.J., van As‐Brooks, C.J., Wedman, J., van der Laan, B.F.A.M.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective The aim of this study was to evaluate the clinical feasibility of the ProTrach DualCare (Atos Medical, Hörby, Sweden), a device combining a hands‐free speaking valve and a Heat and Moisture Exchanger (HME) for tracheotomized patients. Study Design A non‐randomized, prospective single center feasibility study. Methods Sixteen adult tracheotomized patients were included. Participants were asked to test the DualCare for two weeks while continuing their normal activities. After these two weeks, participants could choose whether or not to take part in the long‐term evaluation. The EuroQOL‐5D, Borg scale and questionnaires on speaking, pulmonary function and patient preference were used. During the long‐term evaluation, a minor redesign was implemented and all participants were asked to test the new device again for one week, with a potential long‐term evaluation. Eleven decided to participate. Results The device was well‐tolerated. Speaking noise was reduced (p = 0.020) and speech was considered to sound more natural compared to previously used devices according to the users (p = 0.020). Overall 11 participants preferred the DualCare to their standard device. No serious adverse events were reported. Conclusion Overall, 11 of 16 participants preferred the DualCare to their standard speaking valve or HME. Users of the DualCare were able to use hands free speech with the benefits of an HME and the device was considered clinically feasible and has the potential to improve quality of life of tracheotomized patients. Level of Evidence 2b
ISSN:2378-8038
0023-852X
2378-8038
DOI:10.1002/lio2.124